Stocktoria
Forte Biosciences, Inc. FBRX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-04-13
Forte Biosciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $36,000 | $18.0M | $41,000 | $49,000 |
| R&D expense | — | — | — | — | — | — | $45.3M | $51.1M | $29.1M | $27.2M |
| Operating income | -$70.7M | -$36.6M | -$32.5M | -$13.9M | -$21.5M | -$46.3M | -$4.1M | -$45.9M | -$37.6M | -$31.7M |
| Income tax | $1.0M | $0 | — | — | — | — | $1,000 | $1.7M | $1,000 | $1,000 |
| Net income | -$69.4M | -$35.5M | -$31.5M | -$13.9M | -$21.7M | -$46.5M | -$4.1M | -$49.0M | -$38.9M | -$33.5M |
| EPS (diluted) | $-4.71 | $-12.17 | $-24.92 | $-0.80 | $-1.55 | — | — | — | — | — |
| Operating cash flow | -$50.9M | -$30.7M | -$28.7M | -$8.2M | -$16.7M | -$18.4M | -$2.8M | -$34.5M | -$31.1M | -$29.5M |
| Free cash flow | -$51.0M | -$30.8M | -$28.8M | — | — | — | -$2.9M | -$36.4M | -$31.8M | -$30.1M |
| Cash & equivalents | $77.0M | $22.2M | $37.1M | $41.1M | $42.0M | $58.8M | $6.9M | $40.8M | $35.9M | $5.5M |
| Total assets | $82.8M | $61.6M | $39.0M | $42.0M | $43.3M | $61.2M | $7.7M | $103.1M | $92.1M | $35.4M |
| Total liabilities | $21.8M | $9.1M | — | — | — | — | $17.3M | $44.9M | $21.0M | $28.4M |
| Shareholders' equity | $61.0M | $52.5M | $35.3M | $38.8M | $41.5M | $59.0M | -$4.8M | -$736,000 | $71.1M | -$124.4M |
Growth · year-over-year · Revenue CAGR -9.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -99.8% | +43890.2% | -16.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.